Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression
- 3.7k Downloads
Cancer precursor/progenitor cells may initiate and sustain the growth of tumors, but evidence for their existence in human disease is indirect, relying on their in vitro properties and animal models. More directly, specific elimination of these rare cells from cancer patients should produce a delayed but progressive disappearance of differentiated malignant progeny. Here, we describe selective eradication of a putative precursor population in a patient with B-cell chronic lymphocytic leukemia, followed 6 months later by a progressive loss of mature tumor cells without further treatment. This outcome supports the presence of a rare population of precursor/progenitor cells in human malignancies, and suggests benefit from their removal.
KeywordsChronic Lymphocytic Leukemia Asymmetric Cell Division Precursor Population Human Embryonic Lung Fibroblast Precursor Cell Population
B cell chronic lymphocytic leukemia
peripheral blood mononuclear cells
enzyme-linked immunosorbent spot assay.
Tumors may contain a distinct minority population of "stem cells", but to date only indirect evidence exists that such cells initiate or sustain human cancers [1, 2]. The putative stem cell population has been distinguished by a particular surface phenotype, which may be unique to a given tumor type, or by certain functional properties, such as the ability to efflux Hoechst dyes, which produces a distinct side-population (SP) of cells on fluorescent analysis . Irrespective of their distinguishing characteristics, these subpopulations exhibit asymmetric cell division, enhanced proliferation and greater facility to form tumors in mice [4, 5, 6, 7, 8, 9]. Although suggestive, none of these criteria are definitive of a cancer stem cell, and analysis may be confounded by artifacts of the system used for study . Moreover, some tumor cells, such as those from B cell chronic lymphocytic leukemia (B-CLL) grow poorly in vitro and in animal models, further hampering identification of a true stem cell population. It is not possible to identify a human tumor stem cell population with absolute rigor, since this would require demonstration that only the putative stem cell population could induce disease when administered to human subjects. It is, however, feasible to attempt to demonstrate the reverse, and show how selective removal of a putative stem cell population is followed, after a delay, by the subsequent and progressive loss of the bulk population which is unable to sustain itself past the life span of the "committed" tumor cells. We now describe how administration of a B-CLL tumor cell vaccine generated a transient immune response that selectively and completely removed a putative precursor population, identified by SP analysis, in B-CLL cells from peripheral blood, but had no initial effect on lymphosplenomegaly or total (non-SP) B-CLL cell counts. Continued follow-up over the following 18 months, however, revealed a progressive and continuing reduction in the bulk (non-SP) peripheral blood B-CLL count and in lymphosplenomegaly that began 6 months after completion of immunization and continued progressively over the next 12 months.
At the time of study entry, P1300 was a 65 old male with Stage IV B-CLL, diagnosed 2 years previously. He had received no treatment before vaccination. Pre-vaccination staging showed multiple enlarged lymph nodes by CT scan in the neck, axilla, mediastinum abdomen and inguinal region, splenomegaly (20 × 18 × 8 cm), WBC (31,000/μL), hemoglobin (12.7 gm/dL), platelets (84,000/μL), β2 macroglobulin (4.4 mg/mL), reticulocyte count (1.0%), LDH (211 U/L), diffuse lymphoid infiltrate consistent with B-CLL on bone marrow biopsy, and deletion of 11q and 13q on FISH. After informed consent, he was immunized with CD40L and IL-2 gene-modified, irradiated autologous B-CLL cells on a RAC-NIH, FDA and IRB approved protocol . Briefly, PBMC (>90% CD5/CD19/CD20) were harvested from P1300 and co-cultured on MRC-5 (a human embryonic lung fibroblast cell line; ATCC) transduced with human CD40L and interleukin-2 (IL-2) as previously described . After confirmation of transduction by flow cytometry for hCD40L (94%) and IL-2 secretion (2,412 pg/ml/106 leukemic cells), the gene-modified tumor vaccine was irradiated (30 Gy) and cryopreserved. P1300 subsequently received 6 subcutaneous injections on weeks 0, 1, 2, 6, 8 and 10.
We propose that the selective removal of a putative tumor precursor cell population has resulted in the delayed disappearance of the more "mature" malignant cells from the host, as the pipeline of tumor development became interrupted. Our in vivo clinical data offer support to a substantial body of existing pre-clinical analyses of SP cells that have also suggested that this functional phenotype identifies a precursor cell population for both normal hematopoiesis and other malignancies [3, 11, 12, 13, 14, 15, 16, 17, 18]. While SP analysis uses enhanced export of Hoechst dyes to identify the precursor population, this ABC-transporter mediated activity [19, 20] can also reduce the intracellular concentrations, and thus the effectiveness, of many commonly used chemotherapeutic drugs [11, 12, 13]. Hence, tumor SP cells may therefore both be a tumor precursor population and have the ability to resist common chemotherapeutic agents, contributing to disease persistence or relapse. But although B-CLL SP cells may have greater drug resistance than non-SP cells, our data show that they may also be more sensitive to control by immune T cells than the bulk population. Kipps' group, who first reported that expression of transgenic murine CD40L on autologous B-CLL cells could induce an anti-tumor response after intravenous infusion , have subsequently shown that vaccinated patients develop an antibody response towards ROR1, a tyrosine kinase receptor involved in recognition of Wnt5a and involved in cell motility and asymmetric cell division, characteristics associated with stem cell behavior [22, 23]. While the effects of such immunization on the malignant SP cells in this study are unknown, we hypothesize that differential antigen expression by B-CLL SP cells may allow selective elimination by the immune system. Here, CD40 activation of autologous B-CLL tumor cells may upregulate tumor-associated antigens, such as survivin or RHAMM (receptor for hyaluronic acid-mediated motility) [24, 25] which may be expressed in vivo by B-CLL SP cells, resulting in their depletion following immunization.
In summary, we conclude that circulating B-CLL cells contain at least two distinct populations, SP and non-SP, and that selective removal of the SP component cells can be followed by the delayed disappearance of non-SP in the absence of further treatment or a continuing immune response. These data support the existence of a true tumor precursor population in this human malignancy and suggest benefit from their removal.
This work was supported a SPORE in Lymphoma from the NCI (P50CA126752). We would also like to acknowledge Christopher Threeton and Tatiana Gotsolva for flow cytometry and cell sorting technical assistance.
- 4.Wang JC, Lapidot T, Cashman JD, Doedens M, Addy L, Sutherland DR, Nayar R, Laraya P, Minden M, Keating A, Eaves AC, Eaves CJ, Dick JE: High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 1998, 91: 2406-2414.PubMedGoogle Scholar
- 7.Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007, 104: 973-978. 10.1073/pnas.0610117104PubMedCentralCrossRefPubMedGoogle Scholar
- 8.Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH: Identification of cells initiating human melanomas. Nature. 2008, 451: 345-349. 10.1038/nature06489PubMedCentralCrossRefPubMedGoogle Scholar
- 10.Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M: Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005, 11: 6916-6923. 10.1158/1078-0432.CCR-05-0484CrossRefPubMedGoogle Scholar
- 12.Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA, Jones RJ: Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008, 68: 190-197. 10.1158/0008-5472.CAN-07-3096PubMedCentralCrossRefPubMedGoogle Scholar
- 14.Szotek PP, Chang HL, Brennand K, Fujino A, Pieretti-Vanmarcke R, Lo CC, Dombkowski D, Preffer F, Cohen KS, Teixeira J, Donahoe PK: Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc Natl Acad Sci USA. 2008, 105: 12469-12473. 10.1073/pnas.0805012105PubMedCentralCrossRefPubMedGoogle Scholar
- 17.Sussman RT, Ricci MS, Hart LS, Sun SY, El-Deiry WS: Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther. 2007, 6: 1490-1495. 10.4161/cbt.6.9.4905CrossRefPubMedGoogle Scholar
- 20.Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001, 7: 1028-1034. 10.1038/nm0901-1028CrossRefPubMedGoogle Scholar
- 22.Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, Widhopf GF, Rassenti LZ, Cantwell MJ, Prussak CE, Carson DA, Kipps TJ: Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA. 2008, 105: 3047-3052. 10.1073/pnas.0712148105PubMedCentralCrossRefPubMedGoogle Scholar
- 24.Granziero L, Ghia P, Circosta P, Strola G, Geuna M, Montagna L, Piccoli P, Chilosi M, Caligaris-Cappio F: Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 2001, 97: 2777-2793. 10.1182/blood.V97.9.2777CrossRefPubMedGoogle Scholar
- 25.Giannopoulos K, Mertens D, Buhler A, Barth TF, Moller P, Krober A, Greiner J, Chocholska S, Dmoszynska A, Rolinski J, Dohner H, Stilgenbauer S, Schmitt M: The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia. 2009, 23: 519-527. 10.1038/leu.2008.338CrossRefPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.